PeerView Oncology CME/CNE/CPE Audio Podcast
Summary: PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
- Visit Website
- RSS
- Artist: PVI, PeerView Institute for Medical Education
- Copyright: 2007
Podcasts:
In this program, an expert summarizes current evidence on prognostic and predictive factors in gastrointestinal stromal tumors (GIST), discusses when and how to use mutational analysis in clinical practice, and reviews novel agents and combinations being evaluated in the advanced disease, as well as the emerging role of targeted therapies in patients with early stage GIST.
Please view this PDF file for full CME/CNE information. You will need Adobe Acrobat reader software to access this file.
In this activity, an expert in non-small-cell lung cancer (NSCLC) highlights key clinical data presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Topics of discussion include the potential impact of maintenance therapy on the current NSCLC treatment paradigm, emerging combination regimens and agents for the management of this disease, and the clinical utility of biomarker analysis and tumor cell histology for treatment selection in patients with this malignancy.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this activity, an expert in oncology discusses the current and emerging role of mTOR inhibitors in renal cell carcinoma and other solid tumors.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this activity, an expert in liver diseases discusses clinical issues and the latest evidence in the treatment of hepatocellular carcinoma.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this activity, an expert interprets the latest data on the treatment of advanced colorectal cancer (CRC) with a focus on the clinical implications of these data. Topics covered include the use of multiagent regimens, including combination therapy with biologics; the influence of biomarker testing on treatment selection; and the use of strategies to prevent premature treatment discontinuation, maximize efficacy, and minimize toxicity of current therapies.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this activity, hematology and oncology experts discuss the development and use of epigenetic treatments in cancer. The 3 presentations cover the rationale for targeting epigenetic alterations in cancer, the development and mechanisms of therapies directed against epigenetic targets, and the efficacy and safety of currently available and emerging epigenetic agent classes in solid tumors and hematologic malignancies.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this activity, an expert provides a clinical update on the latest data on molecularly targeted therapies in advanced lung cancer. New strategies with currently approved targeted agents are assessed, and the ongoing exploration of investigational therapies is underscored.
Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.
In this CME activity, experts discuss currently available and emerging immunotherapies for melanoma, with a focus on adjuvant interferon therapy, vaccine strategies, and CTLA-4 antagonists. Recent clinical trial results are reviewed, and the role, benefits, and limitations of the various immunotherapeutic approaches are debated.
